Disclosed are novel alkylarylketocarboxylic acids and 5-substituted tetrazoles represented by the formula ##STR1## wherein Z is aryl or an alkyl of the structure ##STR2## W is a carboxyl moiety or a tetrazole moiety bound to Z at the 5-position of the tetrazole; R.sub.1 is C.sub.4 -C.sub.12 alkyl where Z is aryl and X is oxygen or is C.sub.5 -C.sub.12 alkyl where Z is alkyl and where Z is aryl and X is a bond; R.sub.2 and R.sub.3 are each independently hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy, ...

Propionic and butyric acids substituted in the 3- or 4-position, respectively, with a fluorinated alkoxy group, said alkoxy group terminated with a highly fluorinated branched chain or cyclic fluoroalkoxy group, their nitrile precursors and their esters, salt, amide, N-substituted amide and acid halide derivatives. These compounds are useful as surface-active agents and as oil and water repellency agents.

New salicylic acid compounds, particularly 5-(heterocyclic)-salicylic acid derivatives and process for their preparation are claimed. The new 5-(heterocyclic)salicylic acid compounds described have anti-inflammatory, anti-pyretic and analgesic activity.

A process for polymerizing unsaturated dicarboxylic acids comprises heating the acids in the presence of a catalytic proportion of an unactivated clay and water. The product dimer is distilled to separate unreacted monomer acids. The product dimers of 36, 40 and 44 content are useful as corrosion inhibitors, epoxy resin curing agents, lubricants and intermediates for synthetic polymeric resins and polymeric resin plasticizers.

Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

The present invention relates to phosphinic acid derivatives of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described hereinabove. These compounds can be used in the treatment or prevention of a disease related to the inhibition of .beta.-secretase, inter alia for the treatment of Alzheimer's disease.

Intermediates used in the preparation of compounds of formula I, ##STR00001## or a stereoisomer thereof, or a pharmaceutically acceptable form of either selected from the group consisting of a salt, a solvate and a combination thereof, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid.

The present invention provides a novel carboxylic acid derivative, a salt thereof or a hydrate of them which is useful as an insulin sensitizer, and a medicament comprising the derivative as the effective ingredient. More specifically, it provides a carboxylic acid compound represented by the formula (I), a salt thereof or a hydrate of them. ##STR00001## In the formula, Ar represents a 6- to 14-membered aromatic ring group which may have at least one substituent; R.sup.1, R.sup.2, R.sup.3, R.sup...

Acylaminomethanephosphinic acids, and a process for the preparation of acylaminomethanephosphonic acids and acylaminomethylphosphinic acids Acylaminomethanephosphonic acid and acylaminomethylphosphinic acids of the formula I, in which R.sup.1 is hydroxyl, C.sub.1 -C.sub.4 -alkyl or phenyl and R.sup.2 is H, C.sub.1 -C.sub.6 -alkyl, benzyl or phenyl, unsubstituted or substituted by one or more radicals from the group comprising C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy and halogen, are val...

The invention relates to novel aromatic acids, especially to compounds of formula ##STR1## wherein R.sub.1 is lower alkyl, R.sub.2 is lower alkyl, R.sub.3 is hydrogen, carboxy or sulfo, R.sub.4 is carboxy or sulfo, G is an unsubstituted or substituted 1,4-phenylene group or an unsubstituted or substituted 1,4-naphthylene group, and wherein either R.sub.5 and R.sub.6 together are an additional bond and L is an oxygen or sulfur atom or wherein R.sub.5 is hydrogen, R.sub.6 is halomethyl and L is an...